Novo Nordisk的Mim8试验显示,在预防患血友病A的儿童出血方面取得成功。 Novo Nordisk's Mim8 trial shows success in preventing bleeds in children with haemophilia A.

Novo Nordisk对Mim8的审判,这是对患有血友病A的儿童每周一次的治疗,显示成功,74.3%的参与者出现零治疗出血。 Novo Nordisk's trial of Mim8, a once-weekly treatment for children with haemophilia A, showed success with 74.3% of participants experiencing zero treated bleeds. 该药物的开销良好,可提供更灵活的剂量选择,有可能提高受影响儿童及其家庭的生活质量。 The drug is well-tolerated and could offer more flexible dosing options, potentially improving quality of life for affected children and their families. 向在米兰举行的2025年EAHAD大会提交了成果,预计将在2025年提交监管报告。 Results were presented at the EAHAD 2025 Congress in Milan, with regulatory submissions expected in 2025.